Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEPHROS INCNEPH · Entity 7279 | Director | November 10, 2025 | November 13, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEPHROS INC
Report date November 10, 2025 · Filed November 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 122,881 |
Reported balance
After 2025-11-10 transaction · row 1
1 source rowRow 1 · 2025-11-10 · Grant · Acquired 8,036 · Balance 122,881 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.58 · Expires 2028-08-10 | Direct | 9,466 |
Reported balance
Holding disclosure · report date 2025-11-10 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 9,466 F1: Fully exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.85 · Expires 2028-12-19 | Direct | 5,161 |
Reported balance
Holding disclosure · report date 2025-11-10 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 5,161 F1: Fully exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.57 · Expires 2029-12-16 | Direct | 5,568 |
Reported balance
Holding disclosure · report date 2025-11-10 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 5,568 F1: Fully exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.06 · Expires 2031-01-06 | Direct | 6,850 |
Reported balance
Holding disclosure · report date 2025-11-10 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 6,850 F1: Fully exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.82 · Expires 2031-12-14 | Direct | 7,062 |
Reported balance
Holding disclosure · report date 2025-11-10 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 7,062 F1: Fully exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.07 · Expires 2033-01-05 | Direct | 7,080 |
Reported balance
Holding disclosure · report date 2025-11-10 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 7,080 F1: Fully exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2034-05-14 | Direct | 7,323 |
Reported balance
Holding disclosure · report date 2025-11-10 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 7,323 F2: This option vests as to 2,441 shares on each of 5/14/24, 5/14/25 and 5/14/26. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.47 · Expires 2035-01-01 | Direct | 7,050 |
Reported balance
Holding disclosure · report date 2025-11-10 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 7,050 F3: This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully exercisable.
F2: This option vests as to 2,441 shares on each of 5/14/24, 5/14/25 and 5/14/26.
F3: This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 10, 2025 Filed Nov 13, 2025 21:59 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 8,036 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000040 · form4.xml · nonDerivative · entry 1 Spandow Oliver J. · CIK 0001749836 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,881 Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 22:06 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (Right to Buy) · Derivative | 7,050 | $0.00 Strike: $1.47 | $0.00 |
DisclosureSEC source: 0001062993-25-000233 · form4.xml · derivative · entry 9 Spandow Oliver J. · CIK 0001749836 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,050 Underlying: Common Stock · 7,050 shares Expires 2035-01-01 F4 · derivative.exercise_date: Represents options granted to the reporting person for his service on the Company's Board of Directors for 2024. This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 22:06 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 33,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-000233 · form4.xml · nonDerivative · entry 1 Spandow Oliver J. · CIK 0001749836 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,845 Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:25 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (Right to Buy) · Derivative | 7,323 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001062993-24-010453 · form4.xml · derivative · entry 8 Spandow Oliver J. · CIK 0001749836 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,323 Underlying: Common Stock · 7,323 shares Expires 2034-05-14 F3 · derivative.exercise_date: Represents options granted to the reporting person for his service on the Company's Board of Directors for 2023. This option vests as to 2,441 shares on each of 5/14/24, 5/14/25 and 5/14/26. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 21:48 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 14,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022645 · form4.xml · nonDerivative · entry 1 Spandow Oliver J. · CIK 0001749836 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,604 F1 · shares: Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors for 2023. These shares of restricted stock vest 6 months following the grant date. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:32 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (Right to Buy) · Derivative | 7,080 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001062993-23-000720 · form4.xml · derivative · entry 7 Spandow Oliver J. · CIK 0001749836 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,080 Underlying: Common Stock · 7,080 shares Expires 2032-01-05 F4 · derivative.exercise_date: Represents options granted to the reporting person for his service on the Company's Board of Directors for 2022. This option vests as to 2,360 shares on each of 1/5/23, 1/5/24 and 1/5/25. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:32 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 42,481 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-000720 · form4.xml · nonDerivative · entry 1 Spandow Oliver J. · CIK 0001749836 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,310 F1 · shares: Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors for 2022. These shares of restricted stock vest 6 months following the grant date. Read SEC document |
| December 14, 2021 Filed Dec 17, 2021 02:16 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (Right to Buy) · Derivative | 7,062 | $0.00 Strike: $6.82 | $0.00 |
DisclosureSEC source: 0001437749-21-028834 · rdgdoc.xml · derivative · entry 6 Spandow Oliver J. · CIK 0001749836 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,062 Underlying: Common Stock · 7,062 shares Expires 2031-12-14 F4 · derivative.exercise_date: Represents options granted to the reporting person for his service on the Company's Board of Directors. This option vests as to 2,354 shares on each of 12/14/21, 12/14/22 and 12/14/23. Read SEC document |
| December 14, 2021 Filed Dec 17, 2021 02:16 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 5,429 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-028834 · rdgdoc.xml · nonDerivative · entry 1 Spandow Oliver J. · CIK 0001749836 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,829 F1 · shares: Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors. These shares of restricted stock vest 6 months following the grant date. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:31 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (Right to Buy) · Derivative | 6,850 | $0.00 Strike: $8.06 | $0.00 |
DisclosureSEC source: 0000914190-21-000007 · edgar.xml · derivative · entry 5 Spandow Oliver J. · CIK 0001749836 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,850 Underlying: Common Stock · 6,850 shares Expires 2031-01-06 F4 · derivative.exercise_date: Represents options granted to the reporting person for his service on the Company's Board of Directors. This option vests as to 2,284 shares on 1/6/21 and as to 2,283 shares on each of 1/6/22 and 1/6/23. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:31 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 3,666 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000007 · edgar.xml · nonDerivative · entry 1 Spandow Oliver J. · CIK 0001749836 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,400 F1 · shares: Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors. These shares of restricted stock vest 6 months following the grant date. Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 21:28 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 1,500 | $5.83 | $8,749.20 |
DisclosureSEC source: 0000914190-20-000423 · edgar.xml · nonDerivative · entry 1 Spandow Oliver J. · CIK 0001749836 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,734 Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 22:13 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (Right to Buy) · Derivative | 5,568 | $0.00 Strike: $8.57 | $0.00 |
DisclosureSEC source: 0000914190-19-000507 · edgar.xml · derivative · entry 4 Spandow Oliver J. · CIK 0001749836 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,568 Underlying: Common Stock · 5,568 shares Expires 2029-12-16 F4 · derivative.exercise_date: On December 16, 2019, the Company granted an option to purchase 5,568 shares of common stock of the Company (the "Option") in respect of the service by Mr. Spandow as a member of the Board of Directors of the Company. The Option was granted under the 2015 Plan. The Option vests as to 1,856 shares on each of 12/16/19, 12/16/20 and 12/16/21. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 22:13 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 3,448 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000507 · edgar.xml · nonDerivative · entry 1 Spandow Oliver J. · CIK 0001749836 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,234 F1 · shares: On December 16, 2019, the Company granted 3,448 shares of restricted stock of the Company (the "Restricted Stock") in lieu of cash fees payable to Mr. Spandow in respect of his services as a member of the Board of Directors of the Company. The Restricted Stock was granted under the Company's 2015 Equity Incentive Plan (the "2015 Plan"). The Restricted Stock vests 6 months following the grant date. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:25 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 1,000 | $8.17 | $8,170.00 |
DisclosureSEC source: 0000914190-19-000424 · edgar.xml · nonDerivative · entry 1 Spandow Oliver J. · CIK 0001749836 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,786 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.079 to $8.50. The reporting person undertakes to provide Nephros, Inc., any security holder of Nephros, Inc. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 21:53 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (Right to Buy) · Derivative | 46,457 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0000914190-18-000582 · edgar.xml · derivative · entry 3 Spandow Oliver J. · CIK 0001749836 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,457 Underlying: Common Stock · 46,457 shares Expires 2028-12-19 F3 · derivative.exercise_date: On December 19, 2018, the Company granted an option to purchase 46,457 shares of common stock of the Company (the "Option") in respect of the service by Mr. Spandow as a member of the Board of Directors of the Company. The Option was granted under the 2015 Plan. The Option vests as to 15,486 shares on each of 12/19/18 and 12/19/19, and as to 15,485 shares on 12/19/20. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 22:27 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 18,030 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-18-000567 · edgar.xml · nonDerivative · entry 1 Spandow Oliver J. · CIK 0001749836 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,080 F1 · shares: On December 14, 2018, the Company granted 18,030 shares of restricted stock of the Company (the "Restricted Stock") in lieu of cash fees payable to Mr. Spandow in respect of his services as a member of the Board of Directors of the Company. The Restricted Stock was granted under the Company's 2015 Equity Incentive Plan (the "2015 Plan"). The Restricted Stock vests 6 months following the grant date. Read SEC document |
| August 10, 2018 Filed Aug 13, 2018 20:40 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (Right to Buy) · Derivative | 85,199 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000914190-18-000330 · edgar.xml · derivative · entry 2 Spandow Oliver J. · CIK 0001749836 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,199 Underlying: Common Stock · 85,199 shares Expires 2028-08-10 F1 · derivative.exercise_date: On August 10, 2018, the Company granted to Mr. Spandow an option to purchase 85,199 shares of common stock of the Company, of which one-third vested immediately upon the grant date, one-third will vest on the first anniversary of the grant date, and the remaining one-third will vest on the second anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.